Browse
Prediction results retrieved after performance evaluation of WHO approved 34 primers to estimate their binding affinities for 3892 SARS-CoV-2 variants.

Lineage
(WHO label)
  
Target Gene
  
Primer Name
  
Primer Sequence
  
Primer Length
  
Primer GC Content (%)
  
Start Position
  
End Position
  
Primer Direction
  
ΔG (cal)
  
Primer first used
  
AY.4.9 (Delta)NYoung-NAGCACCATAGGGAAGTCC1855.562864828631R-19874.5Singapore
AY.4.9 (Delta)NChan-NGCGTTCTTCGGAATGTCG1855.562921029227F-21207.6China
B.1.398NUS-CDC-N-2GCGCGACATTCCGAAGAA1855.562923029213R-21404.2US
B.1.398NYoung-NAGCACCATAGGGAAGTCC1855.562864828631R-19874.5Singapore
B.1.398NChan-NGCGTTCTTCGGAATGTCG1855.562921029227F-21207.6China
AY.94 (Delta)NUS-CDC-N-2GCGCGACATTCCGAAGAA1855.562923029213R-21404.2US
AY.94 (Delta)NYoung-NAGCACCATAGGGAAGTCC1855.562864828631R-19874.5Singapore
AY.94 (Delta)NChan-NGCGTTCTTCGGAATGTCG1855.562921029227F-21207.6China
HK.18NUS-CDC-N-2GCGCGACATTCCGAAGAA1855.562923029213R-21404.2US
HK.18NYoung-NAGCACCATAGGGAAGTCC1855.562864828631R-19874.5Singapore
HK.18NChan-NGCGTTCTTCGGAATGTCG1855.562921029227F-21207.6China
B.1.177.18NUS-CDC-N-2GCGCGACATTCCGAAGAA1855.562923029213R-21404.2US
B.1.177.18NYoung-NAGCACCATAGGGAAGTCC1855.562864828631R-19874.5Singapore
B.1.177.18NChan-NGCGTTCTTCGGAATGTCG1855.562921029227F-21207.6China
B.1.177.17NUS-CDC-N-2GCGCGACATTCCGAAGAA1855.562923029213R-21404.2US
B.1.177.17NYoung-NAGCACCATAGGGAAGTCC1855.562864828631R-19874.5Singapore
B.1.177.17NChan-NGCGTTCTTCGGAATGTCG1855.562921029227F-21207.6China
B.1.1.164NUS-CDC-N-2GCGCGACATTCCGAAGAA1855.562923029213R-21404.2US
B.1.1.164NYoung-NAGCACCATAGGGAAGTCC1855.562864828631R-19874.5Singapore
B.1.1.164NChan-NGCGTTCTTCGGAATGTCG1855.562921029227F-21207.6China
B.1.1.275NUS-CDC-N-2GCGCGACATTCCGAAGAA1855.562923029213R-21404.2US
B.1.1.275NYoung-NAGCACCATAGGGAAGTCC1855.562864828631R-19874.5Singapore
B.1.1.275NChan-NGCGTTCTTCGGAATGTCG1855.562921029227F-21207.6China
B.1.258.2NUS-CDC-N-2GCGCGACATTCCGAAGAA1855.562923029213R-21404.2US
B.1.258.2NYoung-NAGCACCATAGGGAAGTCC1855.562864828631R-19874.5Singapore
B.1.258.2NChan-NGCGTTCTTCGGAATGTCG1855.562921029227F-21207.6China
B.1.177.58NUS-CDC-N-2GCGCGACATTCCGAAGAA1855.562923029213R-21404.2US
B.1.177.58NYoung-NAGCACCATAGGGAAGTCC1855.562864828631R-19874.5Singapore
B.1.177.58NChan-NGCGTTCTTCGGAATGTCG1855.562921029227F-21207.6China
B.1.177.81NUS-CDC-N-2GCGCGACATTCCGAAGAA1855.562923029213R-21404.2US
B.1.177.81NYoung-NAGCACCATAGGGAAGTCC1855.562864828631R-19874.5Singapore
B.1.177.81NChan-NGCGTTCTTCGGAATGTCG1855.562921029227F-21207.6China
B.1.1.419NUS-CDC-N-2GCGCGACATTCCGAAGAA1855.562923029213R-21404.2US
B.1.1.419NYoung-NAGCACCATAGGGAAGTCC1855.562864828631R-19874.5Singapore
B.1.1.419NChan-NGCGTTCTTCGGAATGTCG1855.562921029227F-21207.6China
B.1.151NUS-CDC-N-2GCGCGACATTCCGAAGAA1855.562923029213R-21404.2US
B.1.151NYoung-NAGCACCATAGGGAAGTCC1855.562864828631R-19874.5Singapore
B.1.151NChan-NGCGTTCTTCGGAATGTCG1855.562921029227F-21207.6China
B.1.36.2NUS-CDC-N-2GCGCGACATTCCGAAGAA1855.562923029213R-21404.2US
B.1.36.2NYoung-NAGCACCATAGGGAAGTCC1855.562864828631R-19874.5Singapore
B.1.36.2NChan-NGCGTTCTTCGGAATGTCG1855.562921029227F-21207.6China
XBQNUS-CDC-N-2GCGCGACATTCCGAAGAA1855.562923029213R-21404.2US
XBQNYoung-NAGCACCATAGGGAAGTCC1855.562864828631R-19874.5Singapore
XBQNChan-NGCGTTCTTCGGAATGTCG1855.562921029227F-21207.6China
BA.5.6.3NUS-CDC-N-2GCGCGACATTCCGAAGAA1855.562923029213R-21404.2US
BA.5.6.3NYoung-NAGCACCATAGGGAAGTCC1855.562864828631R-19874.5Singapore
BA.5.6.3NChan-NGCGTTCTTCGGAATGTCG1855.562921029227F-21207.6China
CR.1NUS-CDC-N-2GCGCGACATTCCGAAGAA1855.562923029213R-21404.2US
CR.1NYoung-NAGCACCATAGGGAAGTCC1855.562864828631R-19874.5Singapore
CR.1NChan-NGCGTTCTTCGGAATGTCG1855.562921029227F-21207.6China
Lineage
(WHO label)
  
Target Gene
  
Primer Name
  
Primer Sequence
  
Primer Length
  
Primer GC Content (%)
  
Start Position
  
End Position
  
Primer Direction
  
ΔG (cal)
  
Primer first used